News | Nuclear Imaging | June 10, 2017

GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care

Company features high-quality molecular imaging of Discovery MI and Discovery NM/CT 670 CZT at SNMMI, along with upgrade kits for both

GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care

June 10, 2017 — GE Healthcare showcased positron emission tomography (PET) and single photon emission computed tomography/computed tomography (SPECT/CT) advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 that will enable clinicians to deliver personalized, quantitative results to patients. Introduced in 2016, Discovery MI and Discovery NM/CT 670 CZT both offer flexible, digital capabilities that help clinicians guide treatment and support patients with sensitive care while creating an environment for compelling research.

Discovery NM/CT 670 CZT features a state-of-the-art digital detector that represents the next generation of SPECT/CT systems. Powered by the quantitative applications available on GE Healthcare’s nuclear medicine-dedicated workstation, Xeleris 4.0, clinicians can enjoy the certainty of quantitation in customizable, easy-to-read reports across multiple care areas.

According to the company, Discovery NM/CT 670 CZT remains the world’s only general-purpose SPECT/CT imaging system with cadmium zinc telluride (CZT) technology, which enables direct conversion of photons into a digital signal, thus making it more efficient. Over the last year, research collaborations with Rambam Health Center, Barnes-Jewish Hospital, St. Jean Clinic and Hospices Civils de Lyon have demonstrated Discovery NM/CT 670 CZT’s potential impact in guiding patient management, dose reduction and department operations. The system was engineered for patient comfort and to deliver greater than 40 percent improvements in SPECT contrast to noise ratio2, as well as up to a 75 percent dose or time reduction.1

Having the ability to complete multiple scans in a single visit and reduce the injected dose or the scan time represents not only an improved patient experience, but also provides economic and clinical benefits. “The system provides further dose reduction over conventional technologies, and therefore, it could lower the overall cost of radiopharmaceuticals and deliver financial benefits to the nuclear medicine department,” stated Prof. C. Scheiber, Hospices Civils de Lyon, France.

GE Healthcare also introduced Discovery 670 DR, a digital-ready conventional SPECT/CT system, requiring a simple two-day in-field upgrade to CZT technology. The system’s modular design offers an investment protection for easy upgradability to digital. Both Discovery NM/CT 670 CZT and Discovery 670 DR are now powered by the latest 16 slice CT sub-system, offering additional improvements in CT image quality with an overlap reconstruction which enables 32 slices per rotation.

Discovery MI was created to help clinicians diagnose and stage disease earlier and better guide treatment strategies while enabling more compelling research with more novel, faster decaying tracers. Discovery MI brings together the sensitivity of digital detection, with innovative reconstruction technology: the combination of Time-of-Flight (TOF) and Q.Clear. The result is outstanding resolution to improve the detection of small lesions.

“One of the most striking features of Discovery MI is the improved sensitivity,” said Ronny Ralf Buechel, M.D., a cardiologist and nuclear medicine physician from Zurich. “We didn’t know how low we could go with the injected activity and radiation dose, so we began to cautiously lower the dose. Now, we are around 50 percent of the injected dose for PET scans compared to the prior system — around 1 mSv for a complete rest/stress study and what remains important for cardiac imagers is the reduced activity of ammonia without any deterioration in image quality.”

GE plans to introduce a scalable offering to the Discovery MI that will make a three-ring, 15cm axial field of view available, which provides greater access to digital technology to more customers. The three-ring is fully upgradeable in existing units in the field to the 20cm four-ring. With this flexibility, this system is a long-term, fully scalable investment that will allow hospitals to upgrade as patient and department needs change over the years.

GE Healthcare is also introducing Discovery MI DR, a versatile, digital-ready PET/CT system that provides reliable images, faster scan times, low dose and accurate quantitation and allows physicians to image clinically challenging cases, including cardiac and brain imaging. Discovery MI DR’s modular design allows customers to acquire the system that fits their needs and allows for easy and cost-effective upgrade options.

For more information: www.gehealthcare.com

References

1. Together with Clarity 2D/Evolution Technology. Compared to D670 Pro/ES/DR without Clarity 2D/Evolution Technology. Demonstrated in phantom testing using the NEMA IEC Body Phantom.

2. Demonstrated in phantom testing using the NEMA IEC Body Phantom at 50 percent scan times with Evolution Technology.

Related Content

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle

Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

News | PET Imaging | July 16, 2020
July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have b
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

News | PET-CT | July 16, 2020
July 16, 2020 — New research confirms the high impact of...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs

Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs using additional physiologically important parameters, for example, glucose transport rate K1 (d), across the entire body. Image courtesy of G.B. Wang, M. Parikh, L. Nardo, et al., University of California Davis, Calif.

News | PET Imaging | July 16, 2020
July 16, 2020 — Results from the first...
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...
Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the cont

Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the contralateral, asymptomatic side of the neck has an SUVmax = 0.7. This result encouraged a surgeon to explore the area. The surgeon ultimately found a collection of small arteries wrapped around the nerve in this location. The small arteries underwent lysis by the surgeon and the patient reported tremendous relief of symptoms. (A) Coronal thick slab MIP of 18F-FDG PET. (B) Axial LAVA FLEX MRI through the cervical spine. (C) Axial PET at the same slice as the axial MRI. (D) Fused axial PET/MRI. Image courtesy of Cipriano, et al., Stanford University, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — A new molecular imaging approach utilizing 18F-FDG...
Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total

Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total-body PET/CT in osteoarthritis: affected joints include the left elbow, right knee (arrow) and right big toe (arrowhead). Image courtesy of YG Abdelhafez et al., University of California Davis, Sacramento, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneous
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...